SHANGHAI SINOBIOWAY SUNTERRA BIOTECHNOLOGY
Shanghai Sinobioway Sunterra Biotechnology focuses on cutting-edge biotechnology, specifically in the field of adoptive cellular therapies. It was formed by Sinobioway Group, Sunterra Capital, and F1 Oncology for the express purpose of developing novel CAB-CAR-T therapies for solid tumor malignancies in China. SSSB's GMP cell processing facilities in Shanghai have been developed to support clinical research through key academic collaborations.
SHANGHAI SINOBIOWAY SUNTERRA BIOTECHNOLOGY
Status:
Active
Contact:
021-63916608
Technology used in webpage:
Nginx
Current Employees Featured
Founder
Investments List
| Date | Company | Article | Money raised |
|---|---|---|---|
| 2018-01-08 | Exuma Biotech | Shanghai Sinobioway Sunterra Biotechnology investment in Venture Round - Exuma Biotech | 10 M USD |